search
Forge Biologics
Trends
- 1Forge and TECPR2 Foundation Partner on AAV Gene Therapy●Forge, TECPR2 Research Foundation Strike AAV Gene Therapy Development, Manufacturing Partnership
Forge Biologics and the TECPR2 Research Foundation have announced a partnership covering the development and manufacturing of AAV-based gene therapy, aimed at advancing potential treatments for TECPR2-related genetic disorders. The deal combines Forge's manufacturing capabilities with the foundation's research focus, and observers in the biotech industry are watching it as a further example of nonprofits teaming up with contract manufacturers to accelerate rare-disease therapy programs.